Microbiota Directed Food for Children With Severe Acute Malnutrition
NCT ID: NCT06308848
Last Updated: 2024-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
256 participants
INTERVENTIONAL
2024-04-15
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Discharge Trial to Enhance Immunity in Severely Malnourished Children
NCT06530485
The Bangladesh Environmental Enteric Dysfunction Study
NCT02812615
Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot)
NCT03568643
Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
NCT01000298
Meatsafe Food Storage and Diarrhea Prevention Trial in Urban Bangladesh
NCT07332078
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SAM children are found to be suffering from relative gut microbial immaturity, which is related to their growth faltering. Ready-to-use therapeutic food (RUTF) is a key component of the treatment protocol for SAM children and is widely used throughout the world. Which however is found to be partially effective or ineffective in repairing the gut microbial immaturity present in SAM children. To combat this, affordable therapeutic food formulation is needed that can be used to treat acute malnutrition in children with the potential to restore gut microbial colony related to growth and early childhood development.
Knowledge gap: Researchers at icddr,b in collaboration with Washington University in St. Louis has developed a Microbiota-Directed Complementary Food (MDCF) formulation (based on locally available food ingredients) that has the potential of repairing the gut microbiota of children with malnutrition. Results from a recently conducted study of MDCF on Bangladeshi children suffering from moderate acute malnutrition (MAM) showed that the children who received the food exhibited significantly faster rates of ponderal growth compared to those treated with a standard ready-to-use supplementary food. Early evidence, however, is limited to a small sample of children with MAM. This leaves a paucity of data on the role of microbiota directed food interventions on the nutritional as well as microbial recovery and proteomic improvement in children with SAM.
Relevance: To meet the nutritional requirement of SAM children, researchers have come up with a novel intervention named Microbiota-Directed Food (MDF), a ready-to-use therapeutic food by modifying the original MDCF recipe to meet the nutritional requirement of SAM children as well as to make it align with the existing WHO/UNICEF specifications for a nutritional intervention for treating acute malnutrition. The proposed formulation MDF with a relatively lower calorie content will improve the nutritional status by modulating and improving the gut microbial dysbiosis that is present in SAM children. Therefore, the investigators propose this POC trial to generate evidence on the effect of the novel intervention on the ponderal growth, microbial and proteomic recovery among the children with SAM in comparison to the standard RUTF.
Hypothesis: The locally developed MDF would be proven beneficial in nutritional recovery, repairing gut microbiota and restoring plasma biomarkers of healthy growth when compared to standard RUTF among children suffering from SAM.
Primary Objective:
• To assess the role of MDF in improving the weight-for-length Z score (WLZ) of SAM children
Secondary Objectives:
* To investigate the effect of MDF in repairing the gut microbiota of SAM children
* To monitor the change produced by MDF in rebalancing the body composition of the SAM children towards a more appropriate lean-to-fat mass ratio present in SAM children
* To explore the impact of MDF in restoring plasma biomarkers of healthy growth
* To measure the efficacy of MDF in improving the Weight-for-Age Z-score (WAZ) in children with SAM
* To measure the efficacy of MDF in improving the Length-for-Age Z-score (LAZ) in children with SAM
* To assess the acceptability of the MDF among SAM children
* To measure the intake of the MDF by SAM children
Study design:
This will be a double blinded, parallel-group, simple randomized controlled trial.
Study site:
This study will be conducted among residents of Kurigram district. Kurigram District is situated in Northwest Bangladesh (Rangpur Division).
Randomization:
At enrolment, children will be randomized into one of the two intervention arms using permuted block randomization method to ensure even distribution across the intervention arms over time.
Recruitment, Screening and Consenting:
Census, screening, enrolment of study participants will be done in Kurigram. Initially 6-\<24 months old children will be screened by the study health workers through community surveillance by measurement of MUAC (measuring weight and length/height where possible) of the children. Parents of eligible children who meet the inclusion criterion will be approached about enrolment into the study. A trained Field Research Assistant will explain the study in detail, answer any questions from the parent(s), and invite the parent(s) to enroll the child in the study. After acquiring consent from the parents, at the beginning of the study, the child along with his parents will be invited to the study clinic where initial anthropometric assessment (weight, length, MUAC) will be done, and they will be assessed further for eligibility by the study medical personnel regarding any concurrent illness. If found eligible an appetite test will be performed among these children. For the appetite test, standard RUTF will be offered to each child. If a child had a body weight of \<4 kg, then she/he will be offered an amount of 11.5 g, 23 g will be offered if body weight is between 4 and 9.9 kg, 46 g if between 10 and 14.9 kg and 69 g for those ≥15 kg. A child will be considered to have passed the appetite test if she/he consume the required amount according to his/her body weight within 45 minutes. If a child passes the appetite test, then he or she will be considered for enrolment into the study. Our rationale behind the use of 45 minutes as the duration for the appetite test was based on previously published articles.
If the child passes the appetite test, our study research assistant will sought additional information from the parents on the demographic characteristics (families' wealth, standard of housing, family structure and parental characteristics etc.), household food insecurity (HFIAS), vaccination status of the children.
Intervention delivery and feeding:
The study design comprises a 3-month period of nutritional intervention and 12-month post-intervention follow-up. The recommended nutrition for the SAM children is about 150-200 Kcal/kg/day including breast feeding. As the care providers will encourage the study children to receive the diet while continuing to receive their usual diet, the investigators therefore have set the target intake to be 175 kcal/kg/day as per national and international guidelines. Every child will be provided an appropriate amount of the therapeutic diet (\~500kCal/92g sachet) based on their weight from the day of enrolment. Interventions are iso-caloric.
Both the study interventions will be delivered to the homes of participants by project staff on a weekly basis as sachet versions will be produced by a food manufacturing industry. The mother, or the main caregiver will feed the participant at home. The mother/primary caregiver will be instructed to feed the child directly from the sachet. If the child doesn't feel comfortable consuming directly from sachet, they can also spoon or use properly washed hands to feed the diets to their children until s/he refuses to eat. Children will be considered as refusing further intake if they move their head away from the food, cry, clamp the mouth or clinch the teeth, or become agitated, spit out the food or refuse to swallow. Once the child refuses to take, mothers/caregivers will be counselled to give a pause and then try after some time.
Mother/caregiver will be properly trained to monitor their child for any possible side effects/adverse events (e.g., rash, urticaria due to food allergy or any significant changes in clinical status). And if any side effects/adverse events are observed, they will be advised to contact study team immediately. Additionally, the enrolled children will be monitored and caregivers will also be asked every week by trained Field Research Assistants for any illness/side effects/adverse events (e.g., increases in diarrhoea, flatulence, vomiting, skin rash or urticaria due to food allergy or any significant changes in clinical status). If any side effects/adverse events are observed, then they will receive standard care at the nearest health facility or other higher centre if required.
At each weekly food delivery visit, all used and unused food packets from previous week will be collected for weighing in order to estimate intake during the period. In addition, study personnel will ask mothers/caregivers to rate their child's liking of the supplement on 7-point Hedonic scale. A score of 7, will be ranked as 'like extremely' and the lowest value 1 will be ranked as 'dislike extremely'. Hedonic scale data will be collected one week after the initiation of the intervention.
Morbidity data will be collected weekly during the intervention period and bi-weekly during the first three months of the follow-up period.
The Caregiver Reported Early Development Instruments (CREDI) long form will be evaluated for all the children at enrollment, at the end of intervention and three months after finishing intervention.
Food frequency questionnaires (FFQ) will be completed at enrolment, prior to randomization and monthly during the entire intervention period and during the first three months of the follow-up period and three monthly during the rest of the period in order to assess nutrient intake.
Anthropometry:
Anthropometric assessment will be performed by trained study personnel at enrolment, every two weeks interval during the intervention phase and then monthly for the first three months of the follow up period and then at three monthly for the rest of the period until end of the study.
Body composition analysis:
Bioelectrical Impedance Analysis (BIA) is a method of assessing the body composition by measuring the body fat in relation to lean body mass. BIA will be used to measure total fat and fat free at the beginning, at the end of intervention and three months after completing intervention.
Faecal sample collection:
1-2 gm of faecal material will be collected from each child at enrolment, monthly during the intervention period, at the end of intervention and at 4, 5, 6, 9, 12th month during the follow-up period and the end of study.
Blood sample collection:
2 mL of blood samples will be collected from every SAM child at enrolment and just after the intervention is completed and at the 9th month during follow up period and at the end of the study.
Oral swab collection:
Oral swab samples will be collected by using a commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.
Standard care All participants will receive standard care at enrolment and throughout the period of the study, including screening for common illnesses and routine medications, as per the national protocol. Standard treatment for community management of severe acute malnutrition as per national guideline. Treatment for all indicated conditions will be provided as per IMCI guidelines and the national protocol free of charge. All concomitant treatments will be recorded in the appropriate study case report form (CRF).
All caregivers will receive basic nutritional and general health counselling at each visit. Caregivers will be provided with information regarding acute malnutrition as well as the benefits of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Microbiota Directed Food (MDF)
Each participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
Microbiota-Directed Food
MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
Ready-to-Use Therapeutic Food (RUTF)
Each participant will receive 12 weeks of RUTF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
Ready-to-Use Therapeutic Food
RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microbiota-Directed Food
MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
Ready-to-Use Therapeutic Food
RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children aged between 6-\<24 months and with MUAC \<115 mm and/or WLZ \<-3
Exclusion Criteria
* Children with bi-pedal oedema.
* Failed to obtain consent for study participation from parents or legal guardian.
* Suffering from any chronic illness(es) or having severe anemia (\< 8 g/dl).
* History of using antibiotics in the past seven days.
* Children participating in other food intervention programs.
* Children having known history of soy, peanut or milk protein allergy.
* Children who will not pass appetite test.
6 Months
24 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington University School of Medicine
OTHER
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Md Hasan Hafizur Rahman, MPH, MBBS
Role: PRINCIPAL_INVESTIGATOR
International Centre for Diarrhoeal Disease Research, Bangladesh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kurigram Study site
Kurigrām, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR-22077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.